Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propafenone + propranolol is a combination of two cardiac medications that can interact significantly when used together. Propafenone is a class 1c anti-arrhythmic agent that works as a potent sodium channel blocker, while propranolol is a highly lipid-soluble beta-receptor antagonist. When administered together, propafenone significantly increases propranolol plasma levels (by up to 213% for steady-state concentration) by inhibiting its metabolism, while propranolol does not significantly affect propafenone kinetics. This combination can produce additive effects on cardiac function, including reduced blood pressure and heart rate. Due to the potential for increased propranolol toxicity, this combination requires careful monitoring and potential dose adjustments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propafenone + propranolol.